SLC16A1 and B-cell non-Hodgkin lymphoma: The simultaneous targeting of MCT1 inhibitor AZD3965 and the mitochondrial respiratory complex 1 inhibitor IACS01759 is a more clinically relevant strategy compared with targeting only one pathway in B-cell lymphomas [332].